Vir Biotechnology (VIR) PT Raised to $15 at Morgan Stanley

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to Vir Biotechnology (VIR) PT Raised to $15 at Morgan Stanley

Vir Biotechnology (VIR) PT Raised to $19 at Needham

June 5, 2024 12:24 PM EDT

Needham analyst Joseph Stringer raised the price target on Vir Biotechnology (NASDAQ: VIR) to $19.00 (from $15.00) while maintaining a Buy rating.... More

Vir Biotechnology (VIR) Reports Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization

June 5, 2024 5:46 AM EDT

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new preliminary data from its Phase 2 SOLSTICE hepatitis delta clinical trial evaluating tobevibart, an investigational monoclonal antibody, and elebsiran, an investigational small interfering ribonucleic acid, for the treatment of people living with chronic hepatitis delta. Preliminary data from the Phase 2 trial show treatment with tobevibart alone or in combination with elebsiran was generally well tolerated and participants achieved high rates of virologic response at weeks 12 and 24, durable virologic response through 48 weeks, and high rates of ALT normalization.

The Company will host an... More